Protagonist Therapeutics (PTGX) CMO sells 9,514 shares of stock

Rhea-AI Filing Summary

Protagonist Therapeutics Chief Medical Officer Arturo Molina reported a sale of company stock. On January 20, 2026, he sold 9,514 shares of Common Stock at a price of $82.48 per share. The filing explains that this sale was made to cover the tax withholding obligation incurred when restricted stock units settled, meaning the transaction was tied to taxes rather than an open-market portfolio decision. After this sale, Molina beneficially owned 97,266 shares of Protagonist Therapeutics common stock in direct form.

Insider Trade Summary

Net Seller: 9,514 shares ($784,715)

Net Sell 1 txn

Insider MOLINA ARTURO MD

Role Chief Medical Officer

Sold 9,514 shs ($785K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,514	$82.48	$785K

Holdings After Transaction: Common Stock — 97,266 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOLINA ARTURO MD

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CA 94560-1160

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		9,514(1)	D	$82.48	97,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.

	/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTGX report for Arturo Molina?

Protagonist Therapeutics reported that Chief Medical Officer Arturo Molina sold 9,514 shares of Common Stock on January 20, 2026, as shown in the Form 4.

At what price were Arturo Molina's Protagonist Therapeutics (PTGX) shares sold?

The reported sale was for 9,514 shares of Protagonist Therapeutics Common Stock at a price of $82.48 per share.

Why did Protagonist Therapeutics Chief Medical Officer sell 9,514 shares?

The footnote states the sale of 9,514 shares was to cover a tax withholding obligation incurred upon settlement of restricted stock units.

How many Protagonist Therapeutics (PTGX) shares does Arturo Molina own after this transaction?

Following the reported sale, Arturo Molina beneficially owned 97,266 shares of Protagonist Therapeutics Common Stock, held directly.

What is Arturo Molinas role at Protagonist Therapeutics (PTGX)?

According to the filing, Arturo Molina serves as Chief Medical Officer of Protagonist Therapeutics.

Is this Protagonist Therapeutics (PTGX) Form 4 filed by one reporting person or a group?

The Form 4 is indicated as filed by one reporting person, Arturo Molina, rather than by more than one reporting person.